[Behavior of physical endurance and metabolism during acute beta 1 and beta 1/2-blockade]. 1984

W Kindermann, and W Scheerer, and O Salas-Fraire, and G Biro, and A Wölfing

The effect of acute beta 1-blockade (100 mg metoprolol) and beta 1/2-blockade (2 mg levobunolol) on exercise performance and metabolism was studied in 16 healthy male physical education students. The study was carried out in a randomized double blind cross-over fashion. The maximal oxygen uptake was unchanged in all conditions, but maximal exercise capacity was reduced by 4% (beta 1-blockade) and 5% (beta 1/2-blockade). Maximal lactate concentration was reduced by 10% (beta 1-blockade) and 20% (beta 1/2-blockade). In 50 min treadmill exercise with 68% of maximal exercise capacity, beta 1/2-blockade led to premature exhaustion in 50% of subjects. Moreover, blood levels of glucose decreased (in some subjects to about 2.5 mmol X 1(-1], while the values were unchanged under beta 1-blockade. Free fatty acids and glycerol were similarly reduced by both beta-blocking agents. HGH, cortisol, adrenalin, and noradrenalin increased under beta-blockade, but more under beta 1/2-blockade than under beta 1-blockade. Insulin remained unchanged as compared with the unmedicated condition. The perceived exertion was elevated under both beta-blocking agents. CONCLUSIONS Beta 1-blockade affects exercise performance, especially endurance performance, less than beta 1/2-blockade due to unaffected beta 2-receptors mediating glycogenolysis in the skeletal muscles.

UI MeSH Term Description Entries
D008297 Male Males
D008790 Metoprolol A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS. Beloc-Duriles,Betaloc,Betaloc-Astra,Betalok,CGP-2175,H 93-26,Lopressor,Metoprolol CR-XL,Metoprolol Succinate,Metoprolol Tartrate,Seloken,Spesicor,Spesikor,Toprol,Toprol-XL,Beloc Duriles,Betaloc Astra,CGP 2175,CGP2175,H 93 26,H 9326,Metoprolol CR XL,Toprol XL
D010807 Physical Endurance The time span between the beginning of physical activity by an individual and the termination because of exhaustion. Endurance, Physical,Physical Stamina,Stamina, Physical
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004734 Energy Metabolism The chemical reactions involved in the production and utilization of various forms of energy in cells. Bioenergetics,Energy Expenditure,Bioenergetic,Energy Expenditures,Energy Metabolisms,Expenditure, Energy,Expenditures, Energy,Metabolism, Energy,Metabolisms, Energy
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000319 Adrenergic beta-Antagonists Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. Adrenergic beta-Antagonist,Adrenergic beta-Receptor Blockader,Adrenergic beta-Receptor Blockaders,beta-Adrenergic Antagonist,beta-Adrenergic Blocker,beta-Adrenergic Blocking Agent,beta-Adrenergic Blocking Agents,beta-Adrenergic Receptor Blockader,beta-Adrenergic Receptor Blockaders,beta-Adrenoceptor Antagonist,beta-Blockers, Adrenergic,beta-Adrenergic Antagonists,beta-Adrenergic Blockers,beta-Adrenoceptor Antagonists,Adrenergic beta Antagonist,Adrenergic beta Antagonists,Adrenergic beta Receptor Blockader,Adrenergic beta Receptor Blockaders,Adrenergic beta-Blockers,Agent, beta-Adrenergic Blocking,Agents, beta-Adrenergic Blocking,Antagonist, beta-Adrenergic,Antagonist, beta-Adrenoceptor,Antagonists, beta-Adrenergic,Antagonists, beta-Adrenoceptor,Blockader, Adrenergic beta-Receptor,Blockader, beta-Adrenergic Receptor,Blockaders, Adrenergic beta-Receptor,Blockaders, beta-Adrenergic Receptor,Blocker, beta-Adrenergic,Blockers, beta-Adrenergic,Blocking Agent, beta-Adrenergic,Blocking Agents, beta-Adrenergic,Receptor Blockader, beta-Adrenergic,Receptor Blockaders, beta-Adrenergic,beta Adrenergic Antagonist,beta Adrenergic Antagonists,beta Adrenergic Blocker,beta Adrenergic Blockers,beta Adrenergic Blocking Agent,beta Adrenergic Blocking Agents,beta Adrenergic Receptor Blockader,beta Adrenergic Receptor Blockaders,beta Adrenoceptor Antagonist,beta Adrenoceptor Antagonists,beta Blockers, Adrenergic,beta-Antagonist, Adrenergic,beta-Antagonists, Adrenergic,beta-Receptor Blockader, Adrenergic,beta-Receptor Blockaders, Adrenergic
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

W Kindermann, and W Scheerer, and O Salas-Fraire, and G Biro, and A Wölfing
February 1989, Journal of applied physiology (Bethesda, Md. : 1985),
W Kindermann, and W Scheerer, and O Salas-Fraire, and G Biro, and A Wölfing
February 1983, Deutsche medizinische Wochenschrift (1946),
W Kindermann, and W Scheerer, and O Salas-Fraire, and G Biro, and A Wölfing
January 1984, Acta physiologica Scandinavica,
W Kindermann, and W Scheerer, and O Salas-Fraire, and G Biro, and A Wölfing
January 1995, Journal of applied physiology (Bethesda, Md. : 1985),
W Kindermann, and W Scheerer, and O Salas-Fraire, and G Biro, and A Wölfing
January 1993, European journal of clinical pharmacology,
W Kindermann, and W Scheerer, and O Salas-Fraire, and G Biro, and A Wölfing
January 1984, Acta physiologica Scandinavica. Supplementum,
W Kindermann, and W Scheerer, and O Salas-Fraire, and G Biro, and A Wölfing
January 1990, Journal of cardiovascular pharmacology,
W Kindermann, and W Scheerer, and O Salas-Fraire, and G Biro, and A Wölfing
January 1983, Acta medica Scandinavica. Supplementum,
W Kindermann, and W Scheerer, and O Salas-Fraire, and G Biro, and A Wölfing
October 1986, Clinical physiology (Oxford, England),
W Kindermann, and W Scheerer, and O Salas-Fraire, and G Biro, and A Wölfing
November 1982, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
Copied contents to your clipboard!